Huntington’s Disease – Epidemiology – Europe

Clarivate Epidemiology’s coverage of Huntington’s disease (HD) in Europe comprises epidemiological estimates of key patient populations in 12 major mature pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark, Finland, Greece, Netherlands, Norway, Poland, Portugal, Sweden, and Switzerland). We report the prevalence of HD for each country, as well as annualized case counts projected to the national population.

Clarivate Epidemiology’s HD forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the diagnosed prevalent cases, Clarivate Epidemiology forecasts data for the following HD populations:

  • Diagnosed manifest incident cases.
  • Diagnosed manifest prevalent cases.
  • Diagnosed prevalence at risk.
  • Diagnosed manifest stage I prevalent cases.
  • Diagnosed manifest stage II prevalent cases.
  • Diagnosed manifest stage III prevalent cases.
  • Diagnosed manifest stage IV prevalent cases.
  • Diagnosed manifest stage V prevalent cases.
  • Diagnosed prevalence high risk.
  • Diagnosed prevalence low risk.
  • Diagnosed premanifest prevalent cases.
  • Diagnosed manifest drug-treated prevalent cases

Note: Coverage may vary by country.